200 related articles for article (PubMed ID: 8951349)
21. Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage.
Gieseler F; Bauer E; Nuessler V; Clark M; Valsamas S
Leukemia; 1999 Nov; 13(11):1859-63. PubMed ID: 10557063
[TBL] [Abstract][Full Text] [Related]
22. Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II.
Campain JA; Padmanabhan R; Hwang J; Gottesman MM; Pastan I
J Cell Physiol; 1993 May; 155(2):414-25. PubMed ID: 8097746
[TBL] [Abstract][Full Text] [Related]
23. Differential effect of the calmodulin inhibitor trifluoperazine in modulating cellular accumulation, retention and cytotoxicity of doxorubicin in progressively doxorubicin-resistant L1210 mouse leukemia cells. Lack of correlation between cellular doxorubicin levels and expression of resistance.
Ganapathi R; Grabowski D
Biochem Pharmacol; 1988 Jan; 37(2):185-93. PubMed ID: 3342075
[TBL] [Abstract][Full Text] [Related]
24. Inhibitors of calmodulin-dependent protein kinase are nonspecific blockers of voltage-dependent K+ channels in vascular myocytes.
Ledoux J; Chartier D; Leblanc N
J Pharmacol Exp Ther; 1999 Sep; 290(3):1165-74. PubMed ID: 10454491
[TBL] [Abstract][Full Text] [Related]
25. Effects of calcium, calmodulin, protein kinase C and protein tyrosine kinases on volume-activated taurine efflux in human erythroleukemia cells.
Huang CC; Chang CB; Liu JY; Basavappa S; Lim PH
J Cell Physiol; 2001 Dec; 189(3):316-22. PubMed ID: 11748589
[TBL] [Abstract][Full Text] [Related]
26. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
27. Altered drug interaction and regulation of topoisomerase IIbeta: potential mechanisms governing sensitivity of HL-60 cells to amsacrine and etoposide.
Grabowski DR; Holmes KA; Aoyama M; Ye Y; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
Mol Pharmacol; 1999 Dec; 56(6):1340-5. PubMed ID: 10570063
[TBL] [Abstract][Full Text] [Related]
28. [Synergetic cytotoxicity of cisplatin and etoposide to leukemia cell line K562 and its mechanism].
Ma WD; Yin MY; Jiang CW; Xu SR; Zhai LD; Zheng LF; Wang YL; Yan YL
Ai Zheng; 2005 Aug; 24(8):958-64. PubMed ID: 16086873
[TBL] [Abstract][Full Text] [Related]
29. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
30. Effect of KN-62, Ca2+/calmodulin-dependent protein kinase II inhibitor, on adriamycin resistance of human ovarian cancer cells.
Obata NH; Okazaki K; Maeda O; Kikkawa F; Tomoda Y; Hidaka H
Biochem Biophys Res Commun; 1995 Oct; 215(2):566-71. PubMed ID: 7487993
[TBL] [Abstract][Full Text] [Related]
31. Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of beta II protein kinase C.
Ritke MK; Murray NR; Allan WP; Fields AP; Yalowich JC
Mol Pharmacol; 1995 Nov; 48(5):798-805. PubMed ID: 7476909
[TBL] [Abstract][Full Text] [Related]
32. Combined modalities of resistance in etoposide-resistant human KB cell lines.
Ferguson PJ; Fisher MH; Stephenson J; Li DH; Zhou BS; Cheng YC
Cancer Res; 1988 Nov; 48(21):5956-64. PubMed ID: 2844393
[TBL] [Abstract][Full Text] [Related]
33. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
[TBL] [Abstract][Full Text] [Related]
34. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors.
Dubrez L; Goldwasser F; Genne P; Pommier Y; Solary E
Leukemia; 1995 Jun; 9(6):1013-24. PubMed ID: 7596166
[TBL] [Abstract][Full Text] [Related]
35. The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines.
Kurz EU; Wilson SE; Leader KB; Sampey BP; Allan WP; Yalowich JC; Kroll DJ
Mol Cancer Ther; 2001 Dec; 1(2):121-31. PubMed ID: 12467229
[TBL] [Abstract][Full Text] [Related]
36. Calcium-acting drugs modulate expression and development of chronic tolerance to nicotine-induced antinociception in mice.
Damaj MI
J Pharmacol Exp Ther; 2005 Nov; 315(2):959-64. PubMed ID: 16099928
[TBL] [Abstract][Full Text] [Related]
37. Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin.
Kawanami K; Nakamura T; Ono M; Kusano T; Okada K; Kikuchi A; Adachi N; Kohno K; Higashi K; Kuwano M
Oncol Res; 1996; 8(5):197-206. PubMed ID: 8884812
[TBL] [Abstract][Full Text] [Related]
38. Ca(2+)/calmodulin-mediated regulation of the desensitizing process in G(q) protein-coupled histamine H(1) receptor-mediated Ca(2+) responses in human U373 MG astrocytoma cells.
Hishinuma S; Ogura K
J Neurochem; 2000 Aug; 75(2):772-81. PubMed ID: 10899954
[TBL] [Abstract][Full Text] [Related]
39. Role of calcium-calmodulin-dependent protein kinase II in modulation of sensorimotor synapses in Aplysia.
Nakanishi K; Zhang F; Baxter DA; Eskin A; Byrne JH
J Neurophysiol; 1997 Jul; 78(1):409-16. PubMed ID: 9242289
[TBL] [Abstract][Full Text] [Related]
40. Calcium/calmodulin-dependent protein kinase II involvement in release of gonadotropin-releasing hormone.
Waters WW; Chen PL; McArthur NH; Moreno PA; Harms PG
Neuroendocrinology; 1998 Mar; 67(3):145-52. PubMed ID: 9630431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
